GLP-1 Drugs Display Promise in Reducing Addiction Risk

Diabetes and weight-loss medications like Ozempic and Wegovy may offer a surprising benefit: a reduced risk of addiction. A recent large-scale study suggests that glucagon-like peptide-1 (GLP-1) receptor agonists are linked to a lower risk of addiction to substances including alcohol, cocaine, and opioids.

How GLP-1 Agonists May Impact Addiction

Researchers have long theorized that GLP-1 receptor agonists influence the brain’s reward system, a key component in the development of addiction. A study published in The BMJ analyzed data from over 600,000 U.S. Veterans to investigate this connection. The research team, based in Saint Louis, Missouri, sought to determine if the observed pattern would hold up in a large patient cohort.

The study found that veterans without a prior history of substance leverage disorders who took a GLP-1 receptor agonist had a 14 percent lower risk of developing one. Specifically, opioid-related disorders were 25 percent less likely, cocaine and nicotine disorders dropped by 20 percent, alcohol-related disorders by 18 percent, and cannabis-related disorders by 14 percent.

Benefits for Those Already Struggling with Substance Use

The benefits extended to veterans with existing substance use disorders. Compared to those taking alternative diabetes medications (sodium-glucose cotransporter-2 (SGLT-2) inhibitors like Jardiance or Farxiga), GLP-1 users experienced:

• 31 percent fewer emergency room visits related to substance use
• 39 percent fewer overdoses
• 25 percent fewer instances of suicidal ideation or attempts
• Approximately half as many deaths

How Do GLP-1 Agonists Work?

GLP-1 receptor agonists originally gained prominence as treatments for type 2 diabetes. They function by mimicking a naturally occurring hormone that regulates blood sugar. WebMD explains that these drugs also reduce appetite and unhurried digestion, leading to weight loss – a discovery that led to their approval for obesity treatment.

Beyond diabetes and weight management, research suggests potential benefits in cardiovascular health, inflammation reduction, kidney protection, and even neurodegenerative diseases like Alzheimer’s and Parkinson’s.

Study Limitations and Future Research

Researchers acknowledge limitations in the study. The participant pool primarily consisted of older men from the Veterans Affairs healthcare system. However, additional analyses indicated a similar trend in women. As with any observational study, the influence of other factors, such as socioeconomic differences or lifestyle habits, cannot be entirely ruled out.

The researchers emphasize that these findings are preliminary. While the data suggest a potential role for GLP-1 receptor agonists in both preventing and treating substance use disorders, further research is necessary before these drugs can be integrated into routine addiction care. Harvard T.H. Chan School of Public Health also notes the emergence of unregulated GLP-1 supplements, which do not match the effectiveness of prescribed medications like Ozempic and Wegovy.

Semaglutide is the active ingredient in both Ozempic and Wegovy. Wegovy is now available as a once-daily pill, the only semaglutide tablet FDA-approved for weight loss.